Want to see TOVX full AI Analyst Report?
Top Page
Theriva Biologics
(TOVX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.16
▼(-31.67% Downside)
Action:Reiterated
Date:10/31/26
The score is primarily held down by weak financial performance (large losses and ongoing cash burn with a shrinking equity base) and bearish technicals (price below key moving averages with negative MACD and very low RSI). Corporate events provide some pipeline-related upside, but potential dilution actions offset part of that benefit, while valuation inputs are not supportive due to negative earnings and no dividend.
Positive Factors
Clinical pipeline progress
Initiating VIRAGE2 advances VCN-01 into a focused clinical study addressing metastatic pancreatic cancer, the company’s core therapeutic area. The trial is intended to refine dosing and generate evidence that could support a future pivotal Phase 3 program, strengthening the pipeline’s strategic value.
Negative Factors
Minimal commercial traction
The very small revenue base shows that Theriva has not yet demonstrated scalable commercial traction. Persistent minimal or zero annual revenue leaves the company dependent on successful clinical development and eventual approval before it can build a meaningful recurring business.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline progress
Initiating VIRAGE2 advances VCN-01 into a focused clinical study addressing metastatic pancreatic cancer, the company’s core therapeutic area. The trial is intended to refine dosing and generate evidence that could support a future pivotal Phase 3 program, strengthening the pipeline’s strategic value.
Read all positive factors
Theriva Biologics (TOVX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.82M
Dividend YieldN/A
Average Volume (3M)470.97K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue GrowthN/A
EPS Growth94.38%
CountryUS
Employees16
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.67
Shares Outstanding45,892,690
10 Day Avg. Volume417,520
30 Day Avg. Volume470,970
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap0.47
Enterprise Value/Revenue12.33
Enterprise Value/Gross Profit13.40
Enterprise Value/Ebitda-0.32
Forecast
1Y Price Target
$1.00Price Target Upside316.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$300.00K
Theriva Biologics Business Overview & Revenue Model
Company Description
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is e...
Theriva Biologics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
45
Neutral
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 276.00K | -108.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.52M | -23.63M | -19.29M | -21.96M | -19.20M | -14.18M |
| Net Income | -11.62M | -25.25M | -25.65M | -18.35M | -19.68M | -14.27M |
Balance Sheet | ||||||
| Total Assets | 34.86M | 38.24M | 35.35M | 55.22M | 71.86M | 70.36M |
| Cash, Cash Equivalents and Short-Term Investments | 11.34M | 13.06M | 11.61M | 23.18M | 41.79M | 67.33M |
| Total Debt | 3.55M | 2.63M | 1.56M | 2.15M | 1.68M | 1.53M |
| Total Liabilities | 22.67M | 22.86M | 16.29M | 15.52M | 17.30M | 4.96M |
| Stockholders Equity | 12.19M | 15.38M | 19.07M | 39.70M | 54.56M | 65.41M |
Cash Flow | ||||||
| Free Cash Flow | -12.38M | -16.70M | -16.94M | -19.20M | -19.20M | -12.90M |
| Operating Cash Flow | -12.35M | -16.67M | -16.94M | -19.00M | -19.08M | -12.89M |
| Investing Cash Flow | -22.00K | -35.00K | -1.00K | -202.00K | -4.40M | -14.00K |
| Financing Cash Flow | 14.46M | 18.19M | 5.50M | 625.00K | -1.93M | 74.00M |
Theriva Biologics Technical Analysis
Negative
0.24
Price Trends
0.22
Negative
0.23
Negative
0.24
Negative
Market Momentum
-0.01
Positive
26.46
Positive
16.34
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TOVX, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.21, above the 50-day MA of 0.22, and above the 200-day MA of 0.24, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 26.46 is Positive, neither overbought nor oversold. The STOCH value of 16.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TOVX.
Theriva Biologics Risk Analysis
Theriva Biologics disclosed 62 risk factors in its most recent earnings report. Theriva Biologics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Theriva Biologics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $14.42M | >-0.01 | -147.45% | ― | ― | ― | |
44 Neutral | $11.02M | -0.62 | -113.79% | 0.03% | -90.65% | 26.48% | |
43 Neutral | $7.82M | -0.26 | -93.49% | ― | ― | 94.38% | |
42 Neutral | $8.89M | -0.48 | -91.18% | ― | ― | 81.87% | |
41 Neutral | $6.61M | -0.77 | -237.91% | ― | ― | 23.05% | |
41 Neutral | $5.14M | -0.09 | -1539.97% | ― | ― | 80.28% |
* Healthcare Sector Average
TOVX
Theriva Biologics
0.17
-0.16
-47.69%
LSTA
Lisata Therapeutics
1.02
-1.65
-61.80%
AKTX
Akari Therapeutics
8.24
-20.76
-71.59%
XCUR
Exicure
1.01
-3.20
-76.01%
INAB
IN8bio
0.90
-0.98
-52.07%
SNTI
Senti Biosciences
0.17
-1.84
-91.75%
Theriva Biologics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Theriva Begins VIRAGE2 Trial in Metastatic Pancreatic Cancer
Positive
Aug 6, 2026
On August 6, 2026, Theriva Biologics announced it had dosed the first patient in its VIRAGE2 Phase 2a proof-of-concept trial, which is testing more frequent dosing of VCN-01 alongside standard gemcitabine/nab-paclitaxel chemotherapy in first-line ...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Theriva Biologics Expands Stock Incentive and Governance Plans
Positive
Aug 4, 2026
On August 3, 2026, Theriva Biologics, Inc. held its 2026 Annual Meeting of Stockholders, at which shareholders approved Amendment No. 4 to the 2020 Stock Incentive Plan, raising the pool of shares available for equity awards from 4,500,000 to 6,50...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.